Baseline 18F-FDG PET/CT-derived heterogeneity index predicts poor pathological response after neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
Baseline 18F-FDG PET/CT-derived HI, MTV, and TLG may help identify LARC patients at risk for Ryan 3 poor pathological response and the workstation-calculable HI may provide complementary information for pretreatment risk stratification.